Related Experiment Video
Updated: Jun 16, 2026
09:19
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Personalized healthcare in clotting disorders
Personalized Medicine
|February 23, 2010
Summary
Genetic testing for thrombotic disorders guides personalized patient care. Pharmacogenomics of drugs like warfarin and clopidogrel further refines individualized anti-thrombotic therapy based on genetic profiles.
Area of Science:
- Genetics
- Pharmacology
- Internal Medicine
Background:
- Genotype-based care for thrombotic disorders began in 1994 with discoveries of Factor V Leiden and prothrombin gene mutations.
- Genetic testing for thrombophilic single nucleotide polymorphisms (SNPs) is now standard for risk assessment and prophylactic therapy decisions.
Purpose of the Study:
- To highlight the evolution and current state of genotype-guided management of thrombotic disorders.
- To emphasize the role of pharmacogenomics in personalizing anti-thrombotic drug therapy.
Main Methods:
- Review of historical discoveries linking thrombophilic SNPs to thrombotic phenotypes.
- Analysis of the integration of genetic testing into clinical practice for thrombotic risk assessment.
- Examination of recent advancements in pharmacogenomics for anti-thrombotic medications.
Main Results:
- The discovery of Factor V Leiden (G1691A) and prothrombin (G20210A) mutations established the foundation for genetic risk assessment.
- Routine clinical use of genetic tests for thrombophilic SNPs aids in managing thrombotic risk and guiding prophylactic treatments.
- Pharmacogenomic applications in warfarin and clopidogrel therapy represent a significant advancement in personalized medicine.
Conclusions:
- Genotype-based individualized care is crucial for effective thrombotic disorder management.
- Pharmacogenomics is a key driver in tailoring anti-thrombotic therapies to individual patient characteristics.
- Continued integration of genetic insights promises further optimization of thrombotic disorder treatment.
Related Concept Videos
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...